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Introduction: The lung radiosensitivity of the most sensitive patients 
limits doses that can be given to the majority of lung cancer patients. 
The purpose of the current study was to illustrate the concept of per-
sonalizing prescription dose by performing a retrospective study in 
which the prescription is determined using an individualized dose-
volume constraint that is calculated from a toxicity prediction model. 
We test whether using a model-generated personalized lung-dose 
limit results in a clinically significant change to the prescription.
Methods: A model consisting of a dose-volume component and 
a genetic component (single-nucleotide polymorphism informa-
tion) was used to determine iso-risk mean lung-dose (MLD) limits 
for each patient. The prescription dose for each patient was scaled 
according to the individualized MLD constraint and population-
based constraints for the cord, esophagus, and heart. The difference 
between the model-determined prescription dose and the prescription 
the patient was originally treated with was evaluated.
Results: For 59% of the patients the change in prescription using the 
model-determined limit was greater than 5 Gy (either dose escalation 
or de-escalation). For 96% of the patients who developed radiation 
pneumonitis the model predicted that the prescription should have 
been lowered.
Conclusions: Our results indicate that using a model-generated 
personalized MLD results in a clinically different (≥ 5 Gy) pre-
scription. A model used in the manner described by the study can 
help physicians further personalize radiation therapy and aid them 
in determining how much dose can safely be delivered to the tumor 
and normal tissues.
Key Words: Radiation pneumonitis, Radiation toxicity, Dose-response 
modeling, Single-nucleotide polymorphisms.
(J Thorac Oncol. 2012;7: 1676–1682)
Lung cancer remains a major public health concern in the United States. The 5-year survival rate for lung cancer 
patients has been cited at 15%.1 Studies have proposed that 
one possible way to increase local control and subsequently 
overall survival for lung cancer patients is through dose 
escalation to the tumor.2–7 Perez et al.3 randomized patients 
to four different treatment arms, each of which received 
differing radiation doses to the tumor. Bradley et al.5 esca-
lated tumor doses based on the lung receiving 20 Gy (V
20
) 
or more whereas Belderbos et al.6 escalated the target dose 
based on the mean lung dose (MLD). The study reported 
by Kong et al.4 went a step further and explicitly escalated 
the dose using a metric (effective volume) derived from iso-
complication levels determined from a mathematical normal 
tissue complication probability (NTCP) model. Baardwijk 
et al.8 performed an in silico trial in which the potential gain 
in tumor control probability was investigated using an indi-
vidualized maximum tolerable dose prescription. Le et al.7 
reported that higher doses were associated with improved 
local control in patients receiving single-fraction stereotactic 
radiation therapy.
The dose that can be delivered to the tumor is limited by 
normal tissue toxicity. In thoracic radiation therapy the most 
prevalent dose-limiting toxicity is radiation pneumonitis. 
Radiation pneumonitis is an acute effect that generally 
develops within several weeks or months after radiation 
therapy. Symptoms include cough, shortness of breath, fever, 
and if left untreated radiation pneumonitis can be lethal. 
To determine safe radiation doses that can be delivered to 
the healthy lung, clinicians and researchers have turned to 
mathematical NTCP models predicting the rate of radiation 
pneumonitis. Most of the current radiation pneumonitis 
models are based on basic dose-volume histogram (DVH) 
metrics such as MLD.9 In addition to dose volume, studies 
have proposed that other factors such as chemotherapy 
status,10,11 tumor location within the lung,12–14 performance 
status,15 and functional status16,17 of the lung may improve 
prediction for radiation pneumonitis. Another factor that 
has received recent interest is genetic information in the 
form of single-nucleotide polymorphisms (SNPs). SNPs are 
DNA sequence variations that can be used as biomarkers to 
predict for toxicity. Madani et al.18 have published a review 
of biomarkers potentially useful for predicting radiation 
pneumonitis. Yuan et al.19 showed that the CT/CC genotypes 
of the cytokine transforming growth factor B1 (TGFB1) gene 
were associated with a lower risk of radiation pneumonitis. 
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Our group recently analyzed 141 non–small-cell lung 
cancer (NSCLC) patients and demonstrated that SNPs can 
significantly improve the predictive ability of radiation pneu-
monitis toxicity models.20
Lung radiosensitivity is different for each patient. 
Currently, the lung radiosensitivity of the most sensitive 
patients limits the doses that can be given to the major-
ity of the population with thoracic cancers. To account for 
individual radiosensitivity, the next step in individualizing 
radiation therapy is to design treatment based on personal-
ized toxicity estimates (estimates are personalized because 
they account for patient and clinical factors beyond dose 
volume). For example, patients estimated to have a high risk 
of pneumonitis might be considered for different treatment 
modalities whereas patients with a lower risk for pneumonitis 
may be good candidates for dose escalation. Designing treat-
ment plans based on personalized toxicity estimates will be a 
complicated multistep process that will be influenced by the 
increasingly complex toxicity picture and the many ways of 
altering treatment design (escalating dose, replanning using 
the same modality, or replanning using different modalities). 
Rigorous studies are needed that carefully assess each pos-
sible step of the treatment individualization process. In the 
current study, we illustrate the concept of personalizing pre-
scription dose by performing a retrospective proof of princi-
ple virtual trial in which the prescription is determined using 
an individualized dose-volume constraint that is calculated 
from a predictive model. We will use an individualized math-
ematical toxicity model that is composed of a dose-volume 
component and a genetic (SNP) component. The purpose of 
the retrospective study is to present and dosimetrically char-
acterize the concept of scaling the prescription based on indi-
vidualized toxicity estimates.
MATERIALS AND METHODS
SNP Data
The patient database used for the current study was 
taken from our previous SNP work.20 The SNP results will be 
summarized briefly. We used 141 NSCLC patients who were 
treated with definitive radiotherapy (with and without che-
motherapy) at the University of Texas MD Anderson Cancer 
Center from 1999 to 2005. For the study, 16 SNPs from 10 
different genes were genotyped. SNPs were selected based 
on mechanistic considerations (DNA repair, cell cycle, 
tumor necrosis, and angiogenesis). Furthermore, the SNPs 
were selected because they cause nonsynonymous changes 
in amino acids and have been previously reported to be asso-
ciated with cancer risk. The patient population consisted 
of 130 patients treated with three-dimensional conformal 
RT and 11 patients treated with intensity modulated-radia-
tion therapy (IMRT). The endpoint for analysis was severe 
(Common Toxicity Criteria for Adverse Events 3.0 grade 
>3) radiation pneumonitis, which was scored using clinical 
presentation and radiographic findings. The time to radia-
tion pneumonitis was measured from the start of therapy. 
Patients not experiencing the endpoint were censored at 
last follow-up or at the time of local recurrence, if any. The 
Lyman-Kutcher-Burman model was used to estimate the risk 
of radiation pneumonitis as a function of MLD, with SNPs 
and clinical covariates incorporated into the model as dose-
modifying factors (DMFs).20 Five SNPs were identified that 
significantly and independently improved the model fit based 
on MLD. The five SNPs found to predict for radiation pneu-
monitis were within the TGFB073=TT, XRCC_NIH=WW, 
VEGF396=CT, TNF0629=AA, and APEX1=GG genes. 
Studies are underway to validate the original SNP findings20 
in an independent patient cohort. It should be noted that our 
original database contained 141 patients; however, we used 
139 patients for the current study because we were unable 
to de-archive the treatment plans for two patients. The SNP 
study was approved by the MD Anderson Internal Review 
Board.
Normal Tissue Dose Limits
The model used to determine the personalized MLD 
limit is described in detail by Tucker et al.20; we will sum-
marize it briefly here. The NTCP model was composed of a 
dose-volume component and an SNP component. We started 
with the Lyman-Kutcher-Burman formulation for NTCP with 
a DMF incorporated to account for the SNP data. The model 
predicts radiation pneumonitis complication probability as a 
function of dose volume and SNP data, and can be mathemati-
cally written as (1),(2) (3)
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where MLD is the mean lung dose and m and TD50 
are model-fitting parameters. The DMF
T
 is the total dose-
modification factor and is the product of the dose-modification 
factors of the individual SNPs. The dose-volume metric we 
used in the model was MLD because in previous analysis of 
our database we did not find the volume parameter in the DVH 
reduction scheme to be different from 121 and because MLD 
is commonly reported in the modeling literature.9 However, 
the most effective dose-volume metric to be used is a topic of 
ongoing research and should be determined using modeling 
methods for each patient database. The model was fitted 
to the data in our patient database to obtain the following 
parameter estimates: t = 41.6, m = 0.354, DMF
XRCC
 = 1.46, 
DMF
TGFB
 = 1.40, DMF
VEGF
 = 1.39, DMF
TNF
 = 1.9, DMF
APEX
 = 
1.46. Example dose-response curves described by Equations 
1 to 3 are shown in Figure 1. The curves represent different 
possible values for the DMFT, which in turn represent 
different combinations of genotypes of the five SNPs. The 
genotypes of each patient for the five SNPs are known and 
therefore we can determine the complication probability 
curve each patient falls on. The next piece of information 
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that is needed to determine a personalized lung-dose limit is 
the accepted complication probability. Our main simulation 
used a complication probability of 20.1% because that was 
the actuarial toxicity rate of our data set; we also performed 
simulations using 17% and 23% complication probabilities. 
Once we have determined the NTCP curve each patient 
falls on, based on their genotype for the five SNPs, and we 
have a chosen complication probability, we can determine a 
personalized lung-dose limit for each patient. For example, 
based on an iso-complication probability of 20.1% (Fig. 
1), different patients may have genotypes that would call 
for a 6 Gy, 12 Gy, 16.5 Gy, 23 Gy, or 31 Gy MLD limit. 
In addition to the personalized MLD limit, we applied limits 
for the spinal cord (D
max
 ≤ 50), esophagus (V
60
 ≤ 50%), and 
heart (V
50
 ≤ 50%). These limits are in line with the treatment-
planning parameters used in our clinic.
Virtual Trial
The prescription of the original plan was scaled (with 
no change in beam orientation) based on the model-deter-
mined MLD limit and the other treatment-planning param-
eters. If all dose-volume parameters of the patient fell below 
the applied limits, the dose could be escalated; conversely, if 
one of the parameters exceeded the limits, the dose needed 
to be lowered. To calculate the magnitude of dose change we 
computed a ratio of the imposed dose-volume limits and the 
patient’s clinical parameters. The organ with the minimum 
ratio was taken as the dose-limiting organ. For example, if the 
dose could be escalated by 6% according to the lung limit and 
15% according to the spinal cord limit, the lung would be the 
dose-limiting organ and the dose could only be escalated by 
6%. Once the dose-limiting organ was determined, the dose 
escalation or de-escalation scheme dictated by that organ was 
applied to the prescription dose and the other dose-volume 
parameters. The metric we used for evaluation was the dif-
ference between the model-determined prescription dose and 
the prescription the patient was originally treated with. The 
model-determined prescriptions were capped at 40 Gy for the 
lower limit and 100 Gy for the upper limit. The prescription 
dose used for the baseline comparison varied for our patient 
population (range, 60–72 Gy, median 63 Gy). Using vari-
able prescription doses is not ideal; however, we were limited 
to those patients whose blood samples had been collected. 
Furthermore, evaluating the difference between the prescrip-
tions helps mitigate some of the effects associated with a 
variable baseline prescription.
In summary, we scaled the prescription dose for each 
patient according to normal tissue constraints. We used 
conventional dose-volume constraints for the spinal cord, 
esophagus, and heart, and a personalized iso-complication 
MLD limit determined from a mathematical prediction 
model. We investigated the difference between the model-
determined prescription dose and the dose originally 
prescribed for the patient. For 32 patients in the study, the 
clinically used dose-volume values for the spinal cord, 
esophagus, and heart exceeded the dose-volume limits 
imposed for the study (before the model-determined MLD 
limit being applied). This occurred because at the time of 
treatment the clinician made a decision to exceed dose-
volume constraints in favor of better tumor control. We 
performed our simulation both with and excluding patients 
who had exceeded dose-volume constraints (before the MLD 
being applied). The rationale for performing the study both 
ways was that including the 32 patients provides a clinically 
realistic scenario, whereas excluding them helps isolate the 
effect of the personalized MLD limit.
FIGURE 1.  Example radiation 
pneumonitis complication probability 
curves for different SNP combina-
tions. The percentage of the study 
population that falls on each example 
curve is shown. The varying MLD 
limits (in Gy) corresponding to a 
complication probability of 0.201 are 
shown. SNP, single-nucleotide poly-
morphism; MLD, mean lung dose.
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RESULTS
A histogram of the difference between the model-gen-
erated prescriptions and the clinically achieved prescriptions 
is shown in Figure 2. The patients to the left of zero are the 
patients for whom the model dictated that the prescription 
dose needed to be reduced, whereas the patients to the right 
of zero are the patients for whom the model predicted that the 
doses could be escalated. There were 82 patients (59%) who 
had a change in prescription of 5 Gy or more and 26 patients 
(19%) had changes of 20 Gy or more. There were 26 patients 
(19%) who developed radiation pneumonitis (grade ≥3). Of 
the 26 patients who developed pneumonitis, 25 (96%) appear 
to the left of zero (Fig. 2), indicating that for these patients 
the model predicted that the prescription doses needed to be 
reduced. The mean clinical prescription originally prescribed 
to the pneumonitis population was 64.7 Gy whereas the 
model-predicted prescription was 51.8 Gy.
The mean, median, and range of the change in pre-
scription doses are shown in Table 1. The average differ-
ence between the model-generated plans and the clinically 
used plans using a complication probability of 20.1% was 
a reduction of −2.8 Gy (with a median value of −0.4 Gy). 
The mean and median changes in prescription were nega-
tive, implying that overall, the model-predicted doses were 
lower than the clinically achieved doses. This occurred 
because for 32 patients, the dose-volume parameters for 
the clinically used plan exceeded the limits set for this 
study (before applying the model-determined MLD limit). 
Excluding these patients, the mean change in prescription 
was −0.5 Gy (Table 1).
As expected, the simulation using the 23% complica-
tion probability had fewer patients with a negative change 
in prescription and more patients with a positive change in 
prescription than the simulation using the 17% complication 
probability (Fig. 3). The mean and median changes in pre-
scription were higher for the 23% complication probability 
simulation than for the 17% complication probability simula-
tion (Table 1).
FIGURE 2. Histogram showing 
the difference between the model-
generated prescription and the 
prescription the patient was originally 
treated with. Patients who devel-
oped pneumonitis of grade 3 or 
higher are shown in lighter gray. Rx, 
prescription.
TABLE 1.  Model-Generated and Clinically Achieved 
Prescriptions for Complication Probabilities of 17%, 20.1%, 
and 23%
Clinical  
Rx (Gy)
Model  
Rx (Gy)
Model  
Rx–Clinical Rx (Gy)
Complication probability of 20.1
Mean 65.4 62.6 −2.8
Median 63.6 64.3 −0.4
Range 60.0–72.0 40.0–100.0 −29.6 to 37.0
Complication probability of 20.1% reduced patient population
Mean 65.4 64.7 −0.5
Median 63.6 65.1 1.5
Range 60.0–72.0 40–100.0 −27.8 to 37.0
Complication probability of 17%
Mean 65.4 61.4 −4.1
Median 63.6 62.7 −2.5
Range 60.0–72.0 40–100 −30.4 to 37.0
Complication probability of 23%
Mean 65.4 63.5 −1.9
Median 63.6 64.6 0.0
Range 60.0–72.0 40–100 −29.6 to 37.0
The reduced patient population refers to the data set that excluded patients for 
whom the clinically used dose-volume values for the spinal cord, esophagus, and heart 
exceeded the dose-volume limits imposed for the study (before the model-determined 
mean lung-dose limit being applied).
Rx, prescription.
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The dose-limiting organs for all the simulations are 
shown in Table 2. The model-derived lung-dose limit and the 
maximum spinal cord dose were the most frequent dose-lim-
iting organs. The model-generated lung limit was the limiting 
factor for 55% and 43% of the patient population for the 17% 
and 23% complication probability simulations, respectively.
DISCUSSION
The most significant finding of the virtual trial is that 
for individual patients, using a model-generated personalized 
MLD limit results in a clinically different prescription than 
what was used clinically. Specifically, when an SNP-based 
personalized MLD limit is used, 59% of the patient population 
had a change in prescription greater than 5 Gy. Our results 
also dictate that as much as a 20 Gy difference in prescription 
can be observed. For the patients who developed pneumonitis, 
the model predicted a lower dose than what was originally pre-
scribed. The predicted decrease in the prescription for pneu-
monitis patients can partially be explained by the dose-volume 
effect; however, predicted lower prescription values illustrate 
that using a model that further personalizes toxicity estimates 
has the potential to reduce toxicity.
The direction of the change in prescription (dose 
escalation versus de-escalation) depends on the sample 
population used for the modeling study. Using a complication 
probability of 20.1%, the overall change in dose prescription 
was negative (indicating a dose reduction). However, when 
a reduced patient cohort was used, which excluded patients 
for whom initial clinical values exceeded our dose limits, 
the changes in prescription were approximately 0, indicating 
that the positive and negative changes in dose for individual 
patients cancelled out (Table 1). The overall change in 
prescription is also dependent on the exact complication 
probability that is used. As the complication probability is 
increased, the lung-dose limit is relaxed, and we were able to 
increase the prescription dose (Figure 3). These results suggest 
that if data in the current study are used to design a clinical 
trial, the complication probability and study cohort will have 
to be considered. These results also underline the importance 
of determining a proper use of the suggested model. In the 
current simulation, 32 plans would have been unacceptable 
regardless of their genotype (based on constraints for the cord, 
esophagus, and heart). However, at the time, the clinician 
made a clinical judgment to exceed these constraints for 
various reasons (most likely tumor-control considerations). 
The proper use of the model will not be to replace situational 
judgment by the physician or tumor-control considerations 
but rather the model can be used as an aid as the picture for 
toxicity becomes increasingly complicated.
The most frequent dose-limiting organs observed were 
the lung and spinal cord, followed by the esophagus and the 
heart (Table 2). These results are similar to what has been 
observed in our clinic and other dose-escalation studies.16 Our 
results demonstrated that as the allowable lung complication 
FIGURE 3. Histogram showing the 
difference between the model-gen-
erated prescription and the clinically 
achieved prescription for the simula-
tions using complication probabilities 
of 17% and 23%. NTCP, normal 
tissue complication probability; Rx, 
prescription.
TABLE 2.  Dose-Limiting Organ Frequency for Complication 
Probabilities of 17%, 20.1%, and 23%
Dose-Volume Limit
Number of Patients (%)
NTCP = 17.0 NTCP = 20.1 NTCP = 23.0
Model-generated lung limit 77 (55%) 63 (45%) 59 (43%)
Cord 48 (35%) 61 (44%) 64 (46%)
Esophagus 8 (6%) 9 (7%) 10 (7%)
Heart 6 (4%) 6 (4%) 6 (4%)
NTCP, normal tissue complication probability.
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probability is increased from 17% to 23% the lung limit is 
relaxed and the lung becomes a limiting organ for fewer 
cases (55% for the 17% complication probability simulation 
compared with 43% for the 23% complication probability 
simulation).
Van Baardwijk et al.8 performed a simulation study 
using 65 NSCLC patients, in which a lung-dose limit and 
a spinal cord limit were used to escalate doses. The authors 
found that they could increase the tumor dose by 6.6 Gy on 
average. Using IMRT, Lievens et al.22 showed for their patient 
cohort dose escalation of 6.9 Gy using a MLD limit, and a 
dose de-escalation of 2.2 Gy using an esophageal dose-vol-
ume constraint. The discrepancy in the magnitude and direc-
tion of the dose change between the studies can be attributed 
to the differences in study design and the patient popula-
tion. However, the studies by Yolande et al.,22 Van Baardwijk 
et al.,8 and the present study illustrate in silico, that a change 
in dose to the target for lung cancer patients can be achieved 
by prescribing doses that fully use the maximum allowable 
dose values to the normal tissue organs.
Discrimination of patients at a high or low risk for radia-
tion toxicity can facilitate further steps toward treatment per-
sonalization, including dose escalation, radiation modality, 
and schedule selection.18 In future work, the concept of using a 
model to guide patient treatment planning can be expanded in 
several ways. The idea of personalized toxicity estimates can 
be expanded to other organs and other factors that are found to 
be predictive of toxicity in the future. For example, the dose-
volume esophagus constraint can be determined by a model 
that would include chemotherapy status. Another possibility is 
that if it is determined by the toxicity model that a patient can 
withstand a higher MLD, dose can be reduced from another 
organ (spinal cord for example) and redirected through the 
lung. Furthermore, if the model-determined MLD limit can-
not be achieved with three-dimensional conformal RT then the 
toxicity model can provide further justification to use either 
IMRT or proton-radiation therapy. Although the hypothesis 
that proton treatment plans provide more favorable DVHs is 
still under investigation, using a different modality may enable 
the model-determined limit to be achieved for individual 
patients. The replanning step was performed for one patient 
to illustrate the concept. The example patient had an MLD of 
19.48 Gy and the model-determined MLD limit was 14.47 Gy. 
Under the original assumptions of the simulation the prescrip-
tion for this patient would be lowered. Experienced dosime-
trists replanned the patient with IMRT and protons and were 
able to achieve MLD doses of 12.77 and 8.45 Gy, respectively. 
Both the IMRT and protons plans resulted in MLDs below 
the model-determined limit. Treatment personalization has 
the potential to improve tumor control and reduce radiation 
toxicity. However, designing treatment plans based on person-
alized toxicity estimates will be a complicated multistep pro-
cess. The process will be affected by the increasingly complex 
toxicity picture and the many possible variations of altering 
treatment design (escalating or de-escalating dose, replanning 
using the same modality, or replanning using different modali-
ties). Rigorous studies are needed that carefully assess each 
possible step of the individualization process. Although the 
current study does not propose a complete paradigm of treat-
ment personalization we provide data to characterize a signifi-
cant first step in designing plans to accommodate personalized 
toxicity estimates. Future work will incorporate replanning 
and finally the data from the various steps can be combined to 
describe a more complete picture of personalization based on 
individualized toxicity estimates.
The work presented in this study is a proof of principle 
simulation and more work is needed before the proper use of 
a toxicity model can be established. The most important work 
remaining is to verify the SNP results. A study is underway 
to validate the reported relationship between SNPs and tox-
icity20 in an independent patient cohort. If the SNP findings 
are validated, the current study can be used as hypothesis-gen-
erating research for a clinical trial. It should be noted that the 
principles employed in the current simulation are not limited to 
SNPs and can be applied to other factors that are found to be 
predictive for toxicity. It should also be underlined that the cur-
rent study determines prescription doses based on iso-compli-
cation levels for normal tissues and does not take into account 
tumor-control considerations. Tumor control is a primary con-
cern and has to be taken into account when designing clini-
cal trials. Finally, this study does not suggest that the proper 
use of this model is to replace the current treatment-planning 
paradigm. In the replanning example given above, the IMRT or 
proton plans would have to be scrutinized for tumor coverage, 
practical considerations, dose to organs at risk other than the 
lung, and even other dose-volume metrics in addition to MLD. 
The model alone does not replace the clinical judgment of the 
physician, varying patient-by-patient circumstances, or tumor-
control considerations; however, as more factors are incor-
porated in determining toxicity and the picture for radiation 
pneumonitis becomes increasingly complicated, the model can 
be used as a tool to help physicians make clinical decisions.
CONCLUSION
In summary, the current study presents a virtual proof 
of principle simulation trial in which a personalized model-
determined lung-dose limit was used to scale the prescription 
dose. It was determined that for 59% of patients, the change 
in prescription was greater than 5 Gy using the model-deter-
mined limit. The current study provides data to characterize 
a significant first step in designing plans to accommodate 
personalized toxicity estimates. As more factors are found to 
be associated with normal tissue toxicity, a model used in the 
manner proposed can help physicians in determining a safe 
dose to be delivered to the tumor and normal tissues.
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